SPR Gene Sepiapterin Reductase

Total Page:16

File Type:pdf, Size:1020Kb

SPR Gene Sepiapterin Reductase SPR gene sepiapterin reductase Normal Function The SPR gene provides instructions for making the sepiapterin reductase enzyme. This enzyme is involved in the last of three steps in the production of a molecule called tetrahydrobiopterin (BH4). Other enzymes help carry out the first and second steps in this process. The sepiapterin reductase enzyme converts a molecule called 6-pyruvoyl- tetrahydropterin to tetrahydrobiopterin. Tetrahydrobiopterin helps process several building blocks of proteins (amino acids), and is involved in the production of chemicals called neurotransmitters, which transmit signals between nerve cells in the brain. Specifically, tetrahydrobiopterin is involved in the production of two neurotransmitters called dopamine and serotonin. Among their many functions, dopamine transmits signals within the brain to produce smooth physical movements, and serotonin regulates mood, emotion, sleep, and appetite. Health Conditions Related to Genetic Changes Dopa-responsive dystonia At least four mutations in the SPR gene have been found to cause dopa-responsive dystonia. This condition is characterized by a pattern of involuntary muscle contractions ( dystonia), tremors, and other uncontrolled movements and usually responds to treatment with a medication called L-Dopa. Dopa-responsive dystonia can be caused by mutations in one copy or both copies of the SPR gene in each cell. These mutations lead to the production of a sepiapterin reductase enzyme with reduced or absent function. In most parts of the body, there are alternate pathways that do not use sepiapterin reductase for the production of tetrahydrobiopterin, but these processes do not occur in the brain. Therefore, people with sepiapterin reductase deficiency have a lack of tetrahydrobiopterin in the brain, which affects the production of dopamine and serotonin. The lack of these two neurotransmitters causes the movement problems and other characteristic features of dopa-responsive dystonia. Sepiapterin reductase deficiency More than a dozen mutations in the SPR gene have been found to cause sepiapterin reductase deficiency, a condition characterized by progressive problems with movement. Sepiapterin reductase deficiency results when two copies of the SPR gene are mutated Reprinted from MedlinePlus Genetics (https://medlineplus.gov/genetics/) 1 in each cell. These mutations include changes that replace amino acids; alter the way the gene's instructions are pieced together to produce the enzyme; or result in a shortened, nonfunctional enzyme. All these mutations lead to the production of enzymes with reduced or no function. A common mutation in affected individuals that replaces the amino acid arginine with the amino acid glycine at position 150 in the enzyme (written as Arg150Gly or R150G) prevents the production of any sepiapterin reductase. SPR gene mutations disrupt the production of sepiapterin reductase. Most SPR gene mutations result in an enzyme with little or no function. A nonfunctional sepiapterin reductase leads to a lack of tetrahydrobiopterin and a decrease in the production of dopamine and serotonin in the brain. The shortage of these neurotransmitters causes the movement abnormalities and other features of sepiapterin reductase deficiency. Sepiapterin reductase deficiency is more severe than dopa-responsive dystonia likely because both copies of the SPR gene are mutated, which leads to a more severe enzyme shortage than in dopa-responsive dystonia, in which only one copy of the gene has a mutation. Other Names for This Gene • SDR38C1 • sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase) • short chain dehydrogenase/reductase family 38C, member 1 • SPRE_HUMAN Additional Information & Resources Tests Listed in the Genetic Testing Registry • Tests of SPR (https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=6697[geneid]) Scientific Articles on PubMed • PubMed (https://pubmed.ncbi.nlm.nih.gov/?term=%28%28sepiapterin+reductase% 5BTIAB%5D%29+OR+%28SPR%5BTIAB%5D%29%29+AND+%28%28Genes%5B MH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english% 5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D) Catalog of Genes and Diseases from OMIM • SEPIAPTERIN REDUCTASE (https://omim.org/entry/182125) Research Resources Reprinted from MedlinePlus Genetics (https://medlineplus.gov/genetics/) 2 • ClinVar (https://www.ncbi.nlm.nih.gov/clinvar?term=SPR[gene]) • NCBI Gene (https://www.ncbi.nlm.nih.gov/gene/6697) References • Abeling NG, Duran M, Bakker HD, Stroomer L, Thöny B, Blau N, Booij J, Poll- TheBT. Sepiapterin reductase deficiency an autosomal recessive DOPA- responsivedystonia. Mol Genet Metab. 2006 Sep-Oct;89(1-2):116-20. Epub 2006 May 2. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/16650784) • Arrabal L, Teresa L, Sánchez-Alcudia R, Castro M, Medrano C, Gutiérrez-Solana L, Roldán S, Ormazábal A, Pérez-Cerdá C, Merinero B, Pérez B, Artuch R, Ugarte M, Desviat LR. Genotype-phenotype correlations in sepiapterin reductase deficiency. A splicing defect accounts for a new phenotypic variant. Neurogenetics. 2011Aug;12(3) :183-91. doi: 10.1007/s10048-011-0279-4. Epub 2011 Mar 24. Citation on PubMed ( https://pubmed.ncbi.nlm.nih.gov/21431957) • Bonafé L, Thöny B, Penzien JM, Czarnecki B, Blau N. Mutations in thesepiapterin reductase gene cause a novel tetrahydrobiopterin-dependentmonoamine- neurotransmitter deficiency without hyperphenylalaninemia. Am J HumGenet. 2001 Aug;69(2):269-77. Epub 2001 Jul 6. Citation on PubMed (https://pubmed.ncbi.nlm.ni h.gov/11443547) or Free article on PubMed Central (https://www.ncbi.nlm.nih.gov/p mc/articles/PMC1235302/) • Ikemoto K, Suzuki T, Ichinose H, Ohye T, Nishimura A, Nishi K, Nagatsu I,Nagatsu T. Localization of sepiapterin reductase in the human brain. Brain Res.2002 Nov 8; 954(2):237-46. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/12414107) • Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis. 2009Jun;32(3):333- 42. doi: 10.1007/s10545-009-1067-2. Epub 2009 Feb 9. Review.Erratum in: J Inherit Metab Dis. 2009 Jun;32(3):457. Citation on PubMed (https://pubmed.ncbi.nlm.nih.go v/19234759) • Steinberger D, Blau N, Goriuonov D, Bitsch J, Zuker M, Hummel S, Müller U. Heterozygous mutation in 5'-untranslated region of sepiapterin reductase gene( SPR) in a patient with dopa-responsive dystonia. Neurogenetics. 2004Sep;5(3):187- 90. Epub 2004 Jul 6. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/1524165 5) • Zorzi G, Redweik U, Trippe H, Penzien JM, Thöny B, Blau N. Detection ofsepiapterin in CSF of patients with sepiapterin reductase deficiency. Mol GenetMetab. 2002 Feb;75(2):174-7. Citation on PubMed (https://pubmed.ncbi.nlm.ni h.gov/11855937) Genomic Location The SPR gene is found on chromosome 2 (https://medlineplus.gov/genetics/chromosom e/2/). Reprinted from MedlinePlus Genetics (https://medlineplus.gov/genetics/) 3 Page last updated on 18 August 2020 Page last reviewed: 1 May 2012 Reprinted from MedlinePlus Genetics (https://medlineplus.gov/genetics/) 4.
Recommended publications
  • Malignant Hyperphenylalaninemia Tetrahydrobiopterin (BH4) Phenylalanine
    Pediat. Res. 13: 1 150-1 155 (1979) Dihydropterine reductase (DHPR) phenylketonuria malignant hyperphenylalaninemia tetrahydrobiopterin (BH4) phenylalanine Malignant Hyperphenylalaninemia-Clinical Features, Biochemical Findings, and Experience with Administration of Biopterins D. M. DANKS, P. SCHLESINGER, F. FIRGAIRA, R. G. H. COTTON. B. M. WATSON, H. REMBOLD. AND G. HENNINGS Genetics Research Unit, Royal Children S Hospital Research Foundation, and Department of Paediatrics, Universi1.y of Melbourne, Parkville, Australia (D. M. D., P. S., F. F.. R. G. H. C., B. M. W.) and Max Planck Institutfur Biochemie. Germany (H. R., G. H.) Summary has been attributed to defective production of neurotransmitters derived from hydroxylation of tyrosine and of tryptophan (3, 4). Four cases of malignant hyperphenylalaninemia (MHPA) are The results of treatment with L-dopa and 5-hydroxytryptophan described. Pretreatment serum phenylalanine levels were 1.5, 3.0, support this contention (2, 3. 7). 2.4, and 0.9 mmoles/l. Dihydropteridine reductase (DHPR) defi- Four patients with MHPA seen in Melbourne since 1963 are ciency was proven in one patient by assays on cultured fibroblastic presented. One patient has been shown to have DHPR deficiency cells and was presumed in her sibling and in another deceased and her sister is presumed to have died of this defect. Both parents patient whose parents' fibroblastic cells show approximately 50% of another baby had DHPR levels in the heterozygote range of normal enzyme activity. DHPR and phenylalanine hydroxylase suggesting DHPR deficiency as the cause of her death. The 4th deficiency were excluded by assays on liver obtained at autopsy in baby had neither PH or DHPR deficiency and defective BH4 the 4th patient.
    [Show full text]
  • Diosynrhesis of Neopterin, Sepioprerin, Ond Diopterin in Rar Ond Humon Oculor Tissues
    768 INVESTIGATIVE OPHTHALMOLOGY b VISUAL SCIENCE / May 1985 Vol. 26 before and after the addition of beta-glucuronidase.4 ported by the Juvenile Diabetes Foundation and by the University In circumstances where the actual plasma free fluo- of London, Central Research Fund. The HPLC was purchased with an MRC grant to Dr. Michael J. Neal. Submitted for publi- rescein has not been measured, the term "plasma- cation: April 12, 1984. Reprint requests: Dr. P. S. Chahal, Depart- free fluorescence" should be quoted. It is then better ment of Medicine, Hammersmith Hospital, Du Cane Road, London to measure overall fluorescence (fluorescein and the W12 OHS, England. glucuronide metabolite) in protein-free plasma ultra- filtrate and the fluorescence appearing in the ocular References compartments using the same excitor and emission filters. 1. Araie M, Sawa M, Nagataki S, and Mishima S: Aqueous Fluorescein glucuronide is a potential source of humor dynamics in man as studied by oral fluorescein. Jpn J Ophthalmol 24:346, 1980. variability in studies of blood-ocular dynamics using 2. Zeimer RC, Blair NP, and Cunha-Vaz JG: Pharmacokinetic fluorescein. Its exact role has yet to be established. interpretation of vitreous fluorophotometry. Invest Ophthalmol VisSci 24:1374, 1983. Key words: Blood-ocular barriers, diabetes, plasma ultrafil- 3. Chen SC, Nakamura H, and Tamura Z: Studies on metabolite trate, fluorescein glucuronide, fluorescence, protein-binding of fluorescein in rabbit and human urine. Chem Pharmacol Acknowledgments. Technical assistance was given by Dr. Bull 28:1403, 1980. J. Cunningham, Ian Joy, and Margaret Foster. 4. Chen SC, Nakamura H, and Tamura Z: Determination of fluorescein and fluorescein monoglucuronide excreted in urine.
    [Show full text]
  • Isolation and Expression of Rat Liver Sepiapterin Reductase Cdna
    Proc. Nat!. Acad. Sci. USA Vol. 87, pp. 6436-6440, August 1990 Genetics Isolation and expression of rat liver sepiapterin reductase cDNA (tetrahydrobiopterin/biopterin/pyruvoyltetrahydropterin/aromatic amino acid hydroxylase/molecular cloning) BRUCE A. CITRON*, SHELDON MILSTIEN*, JOANNE C. GUTIERREZt, ROBERT A. LEVINE, BRENDA L. YANAK*§, AND SEYMOUR KAUFMAN*¶ *Laboratory of Neurochemistry, Room 3D30, Building 36, and tLaboratory of Cell Biology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892; and tLaboratory of Molecular Neurobiology, Lafayette Clinic, 951 East Lafayette, Detroit, MI 48207 Contributed by Seymour Kaufman, June 7, 1990 ABSTRACT Sepiapterin reductase (7,8-dihydrobiopterin: either case, the final carbonyl reduction to form tetrahydro- NADP+ oxidoreductase, EC 1.1.1.153) catalyzes the terminal biopterin must be catalyzed by sepiapterin reductase. step in the biosynthetic pathway for tetrahydrobiopterin, the In the present study, we have screened a rat liver cDNA cofactor necessary for aromatic amino acid hydroxylation. We library with a specific antibody that reacts positively to the report here the isolation of a cDNA clone for rat liver sepia- enzyme band on Western blots (19). These clones were used pterin reductase. The cDNA has been excised from a lambda to further characterize the enzyme and to begin to elucidate vector and the DNA sequence was determined. The insert the functional sites ofthe enzymes in the tetrahydrobiopterin contains the coding sequence for at least 95% of the rat enzyme biosynthetic pathway. 11 and is fused to the Escherichia coli (3-galactosidase N-terminal segment and the lac promoter. The N-terminal region of the clone contains an extraordinarily high G+C content.
    [Show full text]
  • Epithelial Cell Line Derived from Endometriotic Lesion Mimics Macrophage Nervous Mechanism of Pain Generation on Proteome and Metabolome Levels
    biomolecules Article Epithelial Cell Line Derived from Endometriotic Lesion Mimics Macrophage Nervous Mechanism of Pain Generation on Proteome and Metabolome Levels Benjamin Neuditschko 1,2,† , Marlene Leibetseder 1,† , Julia Brunmair 1 , Gerhard Hagn 1 , Lukas Skos 1, Marlene C. Gerner 3 , Samuel M. Meier-Menches 1,2,4 , Iveta Yotova 5 and Christopher Gerner 1,4,* 1 Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 38, 1090 Vienna, Austria; [email protected] (B.N.); [email protected] (M.L.); [email protected] (J.B.); [email protected] (G.H.); [email protected] (L.S.); [email protected] (S.M.M.-M.) 2 Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, 1090 Vienna, Austria 3 Division of Biomedical Science, University of Applied Sciences, FH Campus Wien, Favoritenstraße 226, 1100 Vienna, Austria; [email protected] 4 Joint Metabolome Facility, Faculty of Chemistry, University of Vienna, Waehringer Straße 38, 1090 Vienna, Austria 5 Department of Obstetrics and Gynaecology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria; [email protected] Citation: Neuditschko, B.; * Correspondence: [email protected] Leibetseder, M.; Brunmair, J.; Hagn, † Authors contributed equally. G.; Skos, L.; Gerner, M.C.; Meier-Menches, S.M.; Yotova, I.; Abstract: Endometriosis is a benign disease affecting one in ten women of reproductive age world- Gerner, C. Epithelial Cell Line wide. Although the pain level is not correlated to the extent of the disease, it is still one of the Derived from Endometriotic Lesion cardinal symptoms strongly affecting the patients’ quality of life.
    [Show full text]
  • Treatable Inborn Errors of Metabolism Presenting As Cerebral Palsy Mimics
    Leach et al. Orphanet Journal of Rare Diseases 2014, 9:197 http://www.ojrd.com/content/9/1/197 RESEARCH Open Access Treatable inborn errors of metabolism presenting as cerebral palsy mimics: systematic literature review Emma L Leach1,2, Michael Shevell3,4,KristinBowden2, Sylvia Stockler-Ipsiroglu2,5,6 and Clara DM van Karnebeek2,5,6,7,8* Abstract Background: Inborn errors of metabolism (IEMs) have been anecdotally reported in the literature as presenting with features of cerebral palsy (CP) or misdiagnosed as ‘atypical CP’. A significant proportion is amenable to treatment either directly targeting the underlying pathophysiology (often with improvement of symptoms) or with the potential to halt disease progression and prevent/minimize further damage. Methods: We performed a systematic literature review to identify all reports of IEMs presenting with CP-like symptoms before 5 years of age, and selected those for which evidence for effective treatment exists. Results: We identified 54 treatable IEMs reported to mimic CP, belonging to 13 different biochemical categories. A further 13 treatable IEMs were included, which can present with CP-like symptoms according to expert opinion, but for which no reports in the literature were identified. For 26 of these IEMs, a treatment is available that targets the primary underlying pathophysiology (e.g. neurotransmitter supplements), and for the remainder (n = 41) treatment exerts stabilizing/preventative effects (e.g. emergency regimen). The total number of treatments is 50, and evidence varies for the various treatments from Level 1b, c (n = 2); Level 2a, b, c (n = 16); Level 4 (n = 35); to Level 4–5 (n = 6); Level 5 (n = 8).
    [Show full text]
  • GCH1 Gene GTP Cyclohydrolase 1
    GCH1 gene GTP cyclohydrolase 1 Normal Function The GCH1 gene provides instructions for making an enzyme called GTP cyclohydrolase 1. This enzyme is involved in the first of three steps in the production of a molecule called tetrahydrobiopterin (BH4). Other enzymes help carry out the second and third steps in this process. Tetrahydrobiopterin plays a critical role in processing several protein building blocks ( amino acids) in the body. For example, it works with the enzyme phenylalanine hydroxylase to convert an amino acid called phenylalanine into another amino acid, tyrosine. Tetrahydrobiopterin is also involved in reactions that produce chemicals called neurotransmitters, which transmit signals between nerve cells in the brain. Specifically, tetrahydrobiopterin is involved in the production of two neurotransmitters called dopamine and serotonin. Among their many functions, dopamine transmits signals within the brain to produce smooth physical movements, and serotonin regulates mood, emotion, sleep, and appetite. Because it helps enzymes carry out chemical reactions, tetrahydrobiopterin is known as a cofactor. Health Conditions Related to Genetic Changes Dopa-responsive dystonia More than 140 mutations in the GCH1 gene have been found to cause dopa-responsive dystonia. This condition is characterized by a pattern of involuntary muscle contractions ( dystonia), tremors, and other uncontrolled movements and usually responds to treatment with a medication called L-Dopa. Dopa-responsive dystonia results when one copy of the GCH1 gene is mutated in each cell. Most GCH1 gene mutations that cause this condition change single amino acids in the GTP cyclohydrolase 1 enzyme. Researchers believe that the abnormal enzyme may interfere with the activity of the normal version of GTP cyclohydrolase 1 that is produced from the copy of the gene with no mutation.
    [Show full text]
  • Inherited Disorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment
    Published online: 2018-10-29 2 Review Article Inherited Disorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment Heiko Brennenstuhl1 Sabine Jung-Klawitter1 Birgit Assmann1 Thomas Opladen1 1 Division of Neuropediatrics and Metabolic Medicine, Department of Address for correspondence Prof. Dr. Thomas Opladen, MD, Division General Pediatrics, University Children’s Hospital Heidelberg, of Neuropediatrics and Metabolic Medicine, Department of General Heidelberg, Germany Pediatrics, Im Neuenheimer Feld 430, D-69120 Heidelberg, Germany (e-mail: [email protected]). Neuropediatrics 2019;50:2–14. Abstract Neurotransmitter deficiencies are rare neurological disorders with clinical onset during childhood. The disorders are caused by genetic defects in the enzymes involved in synthesis, degradation, or transport of neurotransmitters or by defects in the cofactor biosynthesis such as tetrahydrobiopterin (BH4). With the newly described DNAJC12 deficiency, a chaperon-associated neurotransmitter disorder, the pathophysiological spectrum has been broadened. All deficiencies result in a lack of monoamine neurotransmitters, especially dopamine and its products, with a subset leading to decreased levels of serotonin. Symptoms can occur already in the neonatal period. Keywords Classical signs are hypotonia, movement disorders, autonomous dysregulations, and ► inherited monoamine impaired development. Diagnosis depends on quantitative detection of neurotrans- neurotransmitter mitters in cerebrospinal
    [Show full text]
  • Optimization of Expression Conditions Enhances Production Of
    J. Microbiol. Biotechnol. (2015), 25(10), 1709–1713 http://dx.doi.org/10.4014/jmb.1506.06034 Research Article Review jmb Optimization of Expression Conditions Enhances Production of Sepiapterin, a Precursor for Tetrahydrobiopterin Biosynthesis, in Recombinant Escherichia coli Eun-Hee Park1, Won-Heong Lee2, Mi-Hee Jang1, and Myoung-Dong Kim1* 1Department of Food Science and Biotechnology, Kangwon National University, Chuncheon 200-701, Republic of Korea 2Department of Bioenergy Science and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea Received: June 15, 2015 Revised: July 16, 2015 Sepiapterin is a precursor for the synthesis of tetrahydrobiopterin (BH4), which is a well- Accepted: July 18, 2015 known cofactor for aromatic amino acid hydroxylation and nitric oxide synthesis in higher mammals. In this study, a recombinant Escherichia coli BL21(DE3) strain harboring cyanobacterial guanosine 5’-triphosphate cyclohydrolase 1 (GCH1) and human 6- First published online pyruvoyltetrahydropterin synthase (PTPS) genes was constructed to produce sepiapterin. The July 22, 2015 optimum conditions for T7 promoter–driven expression of GCH1 and PTPS were 30°C and *Corresponding author 0.1 mM isopropyl-β-D-thioglucopyranoside (IPTG). The maximum sepiapterin concentration Phone: +82-33-250-6458; of 88.1 ± 2.4 mg/l was obtained in a batch cultivation of the recombinant E. coli, corresponding Fax: +82-33-259-5565; to an 18-fold increase in sepiapterin production compared with the control condition (37°C E-mail: [email protected] and 1 mM IPTG). pISSN 1017-7825, eISSN 1738-8872 Copyright© 2015 by Keywords: Sepiapterin, GTP cyclohydrolase 1 (GCH1), 6-pyruvoyltetrahydropterin synthase The Korean Society for Microbiology (PTPS), Escherichia coli and Biotechnology Tetrahydrobiopterin (BH4) is a well-known essential ovarian cancer cells.
    [Show full text]
  • Two Filipino Patients with 6-Pyruvoyltetrahydropterin Synthase Deficiency
    CASE REPORT Two Filipino Patients with 6-Pyruvoyltetrahydropterin Synthase Deficiency John Karl L. de Dios1,2, Mary Anne D. Chiong,1,2 1Department of Pediatrics, College of Medicine and Philippine General Hospital, University of the Philippines Manila; 2Institute of Human Genetics, National Institutes of Health, University of the Philippines Manila ABSTRACT enzymes: guanosine triphosphate cyclohydrolase Hyperphenylalaninemia can result from defects in either the (GTPCH), 6-pyruvoyltetrahydropterin synthase (PTPS), phenylalanine hydroxylase (PAH) enzyme or in the synthesis or dihydropteridine reductase (DHPR) and pterin-4a- recycling of the active pterin, tetrahydrobiopterin (BH4), which is an carbinolamine dehydratase (PCD). The first two enzymes are obligate co-factor for the PAH enzyme, as well as tyrosine hydroxylase and tryptophan hydroxylase. One of the most common causes of BH4 involved in the biosynthesis of tetrahydrobiopterin, the last 3 deficiency is a defect in the synthesis of 6-pyruvoyltetrahydropterin two in its regeneration. A third enzyme in the biosynthesis synthase (PTPS) enzyme. Patients present with progressive neurological of BH4 is sepiapterin reductase, but its deficiency is not disease such as mental retardation, convulsions and disturbance of associated with hyperphenylalaninemia 1 (Figure 1). tone and posture despite strict adherence to diet and good metabolic Clinical manifestations for a severe PAH defect or BH4 control. The authors report the first two cases of PTPS deficiency in the synthesis/recycling defect can be similar, with patients Philippines. Both are females with initial phenylalanine levels of more presenting with progressive neurological impairment than 1300 umol/L who continued to develop neurologic deterioration during infancy. Since management of these patients will despite good metabolic control and strict adherence to diet.
    [Show full text]
  • 34Th International Winter Workshop Clinical, Chemical and Biochemical
    DOI 10.1515/pterid-2015-0007 Pteridines 2015; 26(3): 113–133 Abstracts*) 34th International Winter Workshop Clinical, Chemical and Biochemical Aspects of Pteridines and Related Topics Society for Exploitation of Education and Research in Immunology and Infectious Diseases, Innsbruck, Austria in collaboration with The International Society of Pteridinology and The Austrian Society of Laboratory Medicine and Clinical Chemistry Held in Innsbruck, Tyrol, Austria, February 24th–27th, 2015 Scientific committee: Dietmar Fuchs (Innsbruck), Andrea Griesmacher (Innsbruck), Bohuslav Melichar (Olomouc), Gilbert Reibnegger (Graz), Barbara Strasser (Hall), Guenter Weiss (Innsbruck) and Ernst R. Werner (Innsbruck) Organization: Dietmar Fuchs, Sektion für Biologische Chemie, Biozentrum, Medizinische Universität Innsbruck, Innrain 80, 6020 Innsbruck, Austria, e-mail: [email protected] *)These abstracts have been reproduced directly from the material supplied by the authors, without editorial alteration by the staff of this Journal. Insufficiencies of preparation, grammar, spelling, style, syntax, and usage are the authors’ responsibility. 114 34th International Winter Workshop Circulating neopterin and citrulline concentrations Influence of carbon nanotubes, ZnO and in patients with germ-cell tumors during gold-doped TiO2 nanoparticles on human PBMC chemotherapy in vitro Bartoušková M, Študentová H, Pejpková I, Zezulová M, Adam T, Becker K, Herlin N, Bouhadoun S, Gostner JM, Ueberall F, Schennach Melichar B H, Fuchs D Palacký University Medical School and Teaching Hospital, Olomouc, Divisions of Biological Chemistry and of Medical Biochemistry, Czech Republic Biocenter, Medical University, and Central Institute of Blood ([email protected]) Transfusion and Immunology, University Hospital, Innsbruck, Austria; Au Service des Photons, Atomes et Molécules - Laboratoire Francis Germ-cell tumors are relatively rare neoplasms that affect mostly Perrin, Gif-sur Yvette, France young adults.
    [Show full text]
  • Building Microbial Factories for The
    Contents lists available at ScienceDirect Metabolic Engineering journal homepage: www.elsevier.com/locate/meteng Building microbial factories for the production of aromatic amino acid pathway derivatives: From commodity chemicals to plant-sourced natural products ∗ Mingfeng Caoa,b,1, Meirong Gaoa,b,1, Miguel Suásteguia,b, Yanzhen Meie, Zengyi Shaoa,b,c,d, a Department of Chemical and Biological Engineering, Iowa State University, USA b NSF Engineering Research Center for Biorenewable Chemicals (CBiRC), Iowa State University, USA c Interdepartmental Microbiology Program, Iowa State University, USA d The Ames Laboratory, USA e School of Life Sciences, No.1 Wenyuan Road, Nanjing Normal University, Qixia District, Nanjing, 210023, China ARTICLE INFO ABSTRACT Keywords: The aromatic amino acid biosynthesis pathway, together with its downstream branches, represents one of the Aromatic amino acid biosynthesis most commercially valuable biosynthetic pathways, producing a diverse range of complex molecules with many Shikimate pathway useful bioactive properties. Aromatic compounds are crucial components for major commercial segments, from De novo biosynthesis polymers to foods, nutraceuticals, and pharmaceuticals, and the demand for such products has been projected to Microbial production continue to increase at national and global levels. Compared to direct plant extraction and chemical synthesis, Flavonoids microbial production holds promise not only for much shorter cultivation periods and robustly higher yields, but Stilbenoids Benzylisoquinoline alkaloids also for enabling further derivatization to improve compound efficacy by tailoring new enzymatic steps. This review summarizes the biosynthetic pathways for a large repertoire of commercially valuable products that are derived from the aromatic amino acid biosynthesis pathway, and it highlights both generic strategies and spe- cific solutions to overcome certain unique problems to enhance the productivities of microbial hosts.
    [Show full text]
  • Ability of RBL2H3 Cells to Lower Environmental Tetrahydrobiopterin Concentration 121
    :-! Hasegawa et a/: Ability of RBL2H3 cells to lower environmental tetrahydrobiopterin concentration 121 Ptendines Vol. 11,2000, pp. 121 - 125 Ability of RBL2H3 Cells to Lower Environmental Tetrahydrobiopterin concen­ tration] 2 2 Hiroyuki Hasegawa ." Kazumasa Yamamoto2J, Yoshie Matsuhashi>, Takahumi Miyazawa , Nobuo Nakanishi., 2 :lnd Kazuya OgUI0 ., :Department of Biosciences and 'Biotechnology Research Center, Teikyo University of Science and Technology. Cenohara, Yamanashi 409-0193, and 'Department of Biochemistry, Meikai University School of Dentistry, Sakado, Saitama 350-0248, Japan This research was supported by the Japan Private School Promotion Foundation, and a Grant-in-Aid for Advanced Scientific Research for Bioscience/Biotechnology areas from the Ministry of Education, Science, Sports and Culture of Japan. Introduction outside the cells. These studies were made by measur­ ing serotonin release with RBL2H3 cells, of a mast Tetrahydrobiopterin works as a redox-cofactor cell-like neoplastic cell origin, and serotorun-loaded inside cells for phenylalanine hydroxylase (1), tyrosine PC-12 cells, of a pheochromocytoma origin, both hav­ hydroxylase (2), tryptophan hydroxylase (3, 4), and ni­ ing ability to release monoamines in response to phys­ tric oxide synthetase (5, 6). Other functions oftetrahy­ iological stimulation. These cells have been employed drobiopterin so far proposed are modulation of more in many studies to explore generic functions of mast complex cellular functions such as mitosis (7, 8), apo­ cells and sympathetic neurons. Between these cells, no ptosis (9··11), and exocytotic release of dopamine (12- essential differences were found with respect to the 14) and serotonin (15). Within them, the suggested BH4-response. Therefore, these observations suggest­ stimulation of monoamine release by BH4, first ed that BH4 might work as a signal mediator to regu­ demonstrated in the rat brain using a microdialysis late cellular functions of a wide variety of cells in tis­ technique by Dr.
    [Show full text]